Zydus Lifesciences Launches India's First Quadrivalent Influenza Vaccine

Zydus Lifesciences has introduced VaxiFlu-4, India's first quadrivalent influenza vaccine, to combat seasonal flu. This vaccine offers protection against four influenza strains, aiming to reduce the mismatch risk and improve public health amid recurring outbreaks, especially in high-risk groups.

Zydus Lifesciences has launched a ground-breaking vaccine, VaxiFlu-4, designed to protect against a new strain of the influenza virus. This development marks India's first quadrivalent influenza vaccine, following the World Health Organization's recommended composition.

The vaccine, which offers coverage for both influenza A and B strains, promises broader protection and minimizes the risk of vaccine mismatch, according to the Ahmedabad-based company. The Central Drug Laboratory has cleared the vaccine, and its development was undertaken at Zydus's Vaccine Technology Centre in Ahmedabad.

Managing Director Sharvil Patel highlights the growing need for accessible, high-quality vaccines in India. VaxiFlu-4's annual immunization could serve as a preventive tool against flu outbreaks, enhancing public health, particularly among high-risk individuals such as children under five, the elderly, and those with chronic conditions.

(With inputs from agencies.)